Ahead of Boston CEO, LeadingBiotech’s eagerly-anticipated event May 28–29 at Boston’s Four Seasons Hotel, here’s a sneak peek at the stellar lineup of senior-level biopharma leaders offering insights into the industry’s biggest challenges and opportunities. Watch the video below to get a flavor of some of the discussions.
“This year’s Boston CEO event has been carefully curated to provide a highly engaging experience for attendees focused on the industry’s most relevant topics and trends,” said LeadingBiotech CEO Wendy Nelson, PhD.
George Church, PhD, Professor of Genetics at Harvard Medical School
In advance of his keynote address, George Church expounds on the future of gene editing and its ethical implications, the potential for Blockchain in reconciling patient privacy and data sharing, and the work he’s doing with the Woolly Mammoth. “We’re mainly reviving genes, not a whole organism,” he says, “using genes that we’ve read from ancient DNA.” He says elephant/mammoth hybrids will even have positive implications for solving climate change.
Laurie Glimcher, MD, President and CEO of Dana-Farber Cancer Institute
Fireside Chat: “Strategic Partnerships & Medical Research Funding”
Laurie Glimcher’s leadership at Dana-Farber is driven by her passion about breakthroughs in cancer research, medical research funding, and the career progression of women. “We’ve made enormous advances in some cancers, we’ve gone into completely different and new areas … but there’s never enough money” for research, she says. “Now is really the time to invest in science and medicine.”
Edward Kaye, MD, CEO at Stoke Therapeutics
Speaker: “Patient Engagement & Advocacy”
Ed Kaye, CEO at Stoke Therapeutics, talks about the importance of patient engagement and advocacy in therapeutic development, saying the patient “is really a partner” in their own therapy. He also gives advice for new CEOs based on his years of experience in the industry and the incredible relationships he has formed.
Andy Plump, MD, Chief Medical and Scientific Officer, Takeda
Closing Keynote Fireside Chat: “Navigating A New Frontier in Biotech”
Andy Plump is CMO and CSO at Takeda at a very exciting time in the company’s history and in the history of drug development and research. He points out, “There’s a huge alignment across the industry that our focus needs to be on the patient, in terms of the significance of the patient in drug discovery.” In this interview, he covers his personal journey as well as the journey of the company since he joined, the new frontier in biotech and why Boston truly is the center of it all.
Paula Soteropoulos, CEO at Akcea Therapeutics
Paula Soteropoulos talks about the challenges of rapid growth at Akcea Therapeutics, including the ability to maintain the culture of the company when the size more than doubled. She emphasizes the importance of the role of women in leadership roles on boards and within a company, saying “It does make a difference! Women tend to bring different styles that we may need today in running businesses.”
These and other leading experts including Bruce Booth, PhD, Partner at Atlas Venture; Jeff Jonas, MD, CEO of Sage Therapeutics; Jeremy Levin, PhD, Chairman & CEO, Ovid Therapeutics, will be on the Boston CEO agenda.
Boston CEO, May 28–29, is part of an exclusive event series bringing biopharma CEOs and leaders together through intimate off-the-record collaboration and dialogue. To request your invitation please email: Suzanne@leadingbiotech.com